Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Combined Immunochemotherapy with FMC + Alemtuzumab in Untreated T-PLL
2008-001421-34Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in T-cell prolymphocytic leukemia (T-PLL), sponsored by University of Cologne. Primary endpoints: Remission rate, Number of serious adverse events and 1 more. Started Oct 2009; status: completed.
02
Drugs
alemtuzumab
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on 2008-001421-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001421-34.